—Genetic loci that are associated with disability in multiple sclerosis have been identified as contributing to its progression, showing that the central nervous system, not the immune system, ...

New clinical trial data suggest vidofludimus calcium can target key mechanisms underlying progressive multiple sclerosis.

In relapse-remitting multiple sclerosis (MS), people experience periods of high MS activity where they have more symptoms or imaging tests show inflammation. Between these periods, the condition might ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) – Late-breaking Phase III FENtrepid ...

People with MS who engage in more physical activity tend to have less severe physical and cognitive disability, a study demonstrated.

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...